Silverback Asset Management’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Silverback Asset Management’s Portfolio OREX Stock Details OREX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-5,040	Closed	-$106	–	48
2015 Q3	$106	Buy	+5,040	New	+$173K	0.01%	42
2014 Q4	–	Sell	-2,590	Closed	-$110K	–	56
2014 Q3	$110K	Buy	+2,590	New	+$139K	0.01%	47

Other funds holding OREX

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Silverback Asset Management's OREX Position: Q1 2016 in Review

Silverback Asset Management sold out of Orexigen Therapeutics, Inc. (OREX) in Q1 2016, closing a stake of 23,733 shares — an estimated $408K sold.

Silverback Asset Management first reported a position in OREX in Q3 2014 and held it in 5 quarters. The position peaked at $1.67M in Q3 2014. 104 funds tracked by Wall St. Rank hold OREX as of Q1 2016.

Silverback Asset Management reported no remaining Orexigen Therapeutics, Inc. position as of Q1 2016 after selling out during the quarter.
Silverback Asset Management sold 23,733 Orexigen Therapeutics, Inc. shares in Q1 2016, an estimated $408K.
Silverback Asset Management first reported a position in Orexigen Therapeutics, Inc. in Q3 2014 and held it in 5 quarters.
Silverback Asset Management's Orexigen Therapeutics, Inc. position peaked at $1.67M in Q3 2014.
104 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q1 2016.

Based on Silverback Asset Management's 13F filing for Q1 2016, filed 13 May 2016.